miR-129-5p ameliorates ischemia-reperfusion injury by targeting HMGB1 in myocardium

Jingxian Xing, Junyan Liu, Juan Liu and Zesheng Xu

Second Department of Cardiovascular Medicine, Cangzhou Central Hospital, Cangzhou, Hebei, People’s Republic of China

Abstract. Globally, acute myocardial infarction (AMI) is a serious condition affecting millions of individuals. While AMI therapy improves blood flow during surgery, reperfusion-induced injury may also occur, leading to secondary cardiac damage or even death. Here, we investigated miR-129-5p in myocardial ischemia-reperfusion (I/R) injury in rats, to explore reperfusion-related molecular mechanisms in myocardium. We used Sprague Dawley rats to establish a myocardial I/R model, with agomiR-129-5p injection, and used rat cardiomyocytes (H9c2) treated with anoxia-reoxygenation (A/R) to mimic myocardial I/R injury in vitro. A dual-luciferase reporter assay determined miR-129-5p binding to high mobility group box-1 (HMGB1) in H9c2 cells. We showed that exogenous miR-129-5p restored cardiac function indices, alleviated cardiac injury, relieved inflammatory effects and reduced infarct size and cell apoptosis in rat myocardium after I/R treatment. Elevated miR-129-5p induced a reduction in HMGB1 expression in rat I/R myocardium. miR-129-5p also targeted HMGB1, and negatively regulated its expression in H9c2 cells. Moreover, miR-129-5p overexpression in the cardiomyocytes reduced cell apoptosis and recovered cell viability after A/R injury, which was reversed by subsequent HMGB1 overexpression. These findings suggest miR-129-5p plays a cardioprotective role in ameliorating myocardial I/R injury in rats, by negatively targeting HMGB1. This mechanism provides new insights into the treatment of myocardium reperfusion-related damage.

Key words: Myocardial reperfusion — I/R injury — miR-129-5p — HMGB1 — Myocardial infarction

Introduction

Acute myocardial infarction (AMI) manifests as myocardial necrosis, due to acute myocardial ischemia accompanied by acute myocardial injury. The condition is characterized by dysfunctional cardiac biomarkers, which contribute to significant morbidity and mortality (Thygesen et al. 2018). Annually, AMI affects the health and life quality of more than seven million individuals, on a global level (Reed et al. 2017). Blood flow improvement or myocardial reperfusion via antithrombotic therapies or primary percutaneous coronary intervention (PCI), or combinations thereof, are effective strategies in limiting myocardial infarct size and improving clinical outcomes for AMI patients (Yellon and Hausenloy 2007; Reed et al. 2017). However, myocardial reperfusion injury often occurs, causing extra myocardium damage or even death (Yellon and Hausenloy 2007). Although ischemic conditioning during myocardial reperfusion is a useful cardioprotective strategy in recent decades, the numbers of subsequent heart failure episodes and other comorbidities have not declined (Hausenloy and Yellon 2016). Therefore, the amelioration of myocardial ischemia-reperfusion (I/R) injury is of particular clinical interest.

Endogenous microRNAs (miRNAs, ~22 nucleotides) have been studied extensively due to their powerful biological regulation of target genes at transcriptional and post-transcriptional levels, and are associated with various disease processes (Ha and Kim 2014; Pu et al. 2019). In heart physiology, multiple miRNAs are aberrantly expressed during myocardial infarction (MI) and MI-related protective mechanisms, and are regarded as potential biomarkers or therapeutic targets for cardiac diseases (Colpaert and Calore 2019; Kura et al. 2020). The identification and charac-
terization of novel miRNAs implicated in cardiac regulation could uncover underlying molecular mechanisms of MI and myocardial reperfusion injury (Kura et al. 2020). Recently, in myocardial cells, miR-129-5p was shown to inhibit hydrogen peroxide (H$_2$O$_2$)-induced cell autophagy and apoptosis, via a PI3K/Akt/mTOR signaling circuit, by targeting ATG14 (Zhang et al. 2018). Moreover, Li et al. (2017) demonstrated that miR-129-5p was downregulated after spinal cord I/R injury in mice, whereas miR-129-5p overexpression ameliorated I/R-induced neuro-inflammation and blood-spinal cord barrier damage by directly targeting the cytokine, high mobility group box-1 (HMGB1). Equally, miR-129-5p was also shown to protect against hypoxia-ischemia brain injury, through distinct targets in neonatal mice and rats (Zhou et al. 2018a, 2018b). However, the effects of miR-129-5p on myocardial I/R injury have yet to be reported.

HMGB1 is a binding target of miR-129-5p (Li et al. 2017; Liu et al. 2017a), with two main functions; the specific structure of HMGB1 confers its function as a transcription factor to bind to and bend DNA to assemble nucleoprotein complexes, and HMGB1 also serves as an extracellular factor to bind to and bend DNA to assemble nucleoprotein complexes, and HMGB1 also serves as an extracellular growth mediator with crucial roles in inflammation and wound repair (Ranzato et al. 2012; Lee et al. 2015). Previously, the expression of HMGB1 was shown to be upregulated during I/R injury, either at the heart or liver, whereas HMGB1 downregulation alleviated I/R injury and also its following inflammatory response (Andrassy et al. 2008; Dong et al. 2018; Xie et al. 2018). This evidence suggests that miR-129-5p may also ameliorate myocardial I/R injury by targeting HMGB1, therefore we tested this hypothesis in this study.

Materials and Methods

Animals

Eight-week-old male Sprague Dawley (SD) rats (Liaoning Changsheng Biotechnology Co., Ltd., China) were used for in vivo work. All animals were kept in a 12 h light/dark cycle at a temperature of 22 ± 1°C, 45–55% humidity with free access to food and water for one week of adaptive feeding. All animal experiments were approved by the Ethics Committee of Cangzhou Central Hospital and all experimental protocols were performed following the Guide for the Care and Use of Laboratory Animals (National Research Council Committee for the Update of the Guide for the and Use of Laboratory 2011).

Animal modeling and myocardial I/R injury

Animals were randomly divided into four groups: Sham, I/R, I/R+agomiR-NC (negative control), and I/R+agomiR-129-5p (GenePharma, Shanghai, China). Each group contained six animals. For in vivo transfection of miR-129-5p reagents, a left thoracotomy was performed on rats and agomiR-NC or agomiR-129-5p (0.5 nmol per animal) was mixed with Entranster®-in vivo (8 μl) (Engreen Biosystem Co., Ltd., Beijing, China), and injected into the anterior wall of the left ventricle of rat myocardium, at six random points (Fu et al. 2017). Rats in the Sham and I/R groups were injected with an equal amount of the transfection reagent. After suturing the wound and a four day recovery, rats were killed and myocardium was collected to examine miR-129-5p expression levels by real-time PCR.

Once miR-129-5p was confirmed as upregulated in relevant groups, the I/R injury model was instigated through left anterior descending (LAD) ligation surgery, after agomiR-129-5p (or agomiR-NC) re-injection into intact animals for four days. Briefly, rats were anesthetized by pentobarbital sodium using intraperitoneal injection (i.p.). After fixation, the neck trachea was incised and exposed to perform endotracheal intubation and ventilation. A left thoracotomy was carried out between the third and fourth intercostal space, and an MI model was formed by blocking blood flow in the anterior descending branch using a sterile 5-0 suture (Shanghai Yuhan Medical Appliance Co., Ltd., China) ligation. Animals in the Sham group had similar procedures without tying the suture. After ligation for 45 min, coronary artery blood flow was restored and reperfused for 3 h. Cardiac function was then examined, and myocardium tissue and serum from different groups collected (Fig. 1). Some myocardium tissue was cryopreserved in liquid nitrogen and stored at –70°C, while other tissue was fixed in 4% paraformaldehyde for further experiments and 2, 3, 5-triphenyltetrazolium chloride (TTC, Solarbio, Beijing, China) staining, according to manufacturer instructions. The MI size in each sample after TTC staining was quantified using Image Pro-Plus (IPP) 6.

Cardiac function measurement

Rats were anesthetized by pentobarbital sodium (50 mg/kg) by i.p. Ultrasound of the left ventricle (LV) was performed using a GE Vivid 7 Dimension ultrasound apparatus (probe M12S, frequency range 4–12 MHz). The ejection fraction (EF) and fractional shortening (FS) in each group were calculated. Then, rat neck was incised and the right carotid artery separated. After ligating the distal end, and clamping the proximal end, a polyethylene catheter (inner diameter: 0.5 mm, outer diameter: 1 mm), filled with 500 U/l heparin sodium and saline solution, was slowly inserted into the LV. Meanwhile, a pressure sensor was connected to the other end of the catheter to collect the data of left ventricular systolic pressure (LVSP) and left ventricular end-diastolic pressure (LVEDP).
miR-129-5p regulates myocardial I/R injury

Cell culture and cell transfection

Rat myocardial H9c2 cells were purchased from Shanghai Zhongqiaoxinzhou Biotech (China), and cultured in Dulbecco’s Modified Eagle Medium (DMEM, HyClone, Logan, Utah, USA) with 10% fetal bovine serum (FBS, Biological Industries, Beit-Haemek, Israel) at 37°C in 5% CO₂. One day before transfection, cells (~90% confluency) were seeded in 6-well-plates, and cultured in serum-free medium for 1 h, followed by Lipofectamine™ 2000 transfection reagent (Invitrogen, Thermo Fisher Scientific, Carlsbad, CA, USA)-mediated transfection based on manufacturer instructions. Briefly, H9c2 cells were transfected with 100 pmol agomiR-129-5p/antagomiR-129-5p/NC or 50 pmol agomiR-129-5p + 1 μg pcDNA3.1+ (Clontech, CA, USA) containing HMGB1 (or empty) in each well, with addition of 8 μl of Lipofectamine™ 2000. After transfection, cells were cultured at 37°C in 5% CO₂.

Anoxia-reoxygenation (A/R) injury in vitro

A/R treatment was conducted 48 h after transfection. Cells cultured in serum-free and glucose-free DMEM were incubated in 95% N₂, 5% CO₂ for 3 h, after which media was replaced with complete DMEM containing 10% FBS, and cells incubated in 95% air, 5% CO₂ for 2 h. Afterward, cells were processed (Fig. 1).

Enzyme activity and inflammatory marker analysis

Serum creatinine kinase (CK) and lactate dehydrogenase (LDH) activities were measured using CK and LDH assay kit, respectively (Nanjing Jiancheng Bioengineering Institute, China) according to manufacturer protocols. ELISA kits for serum interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) (Cloud-Clone Corp., Wuhan, China) determination were used in accordance with manufacturer instructions.

Immunofluorescence-TUNEL (IF-TUNEL) assay

Paraffin tissue sections were de-waxed and rehydrated by xylene and ethanol, respectively. Permeabilization was performed using 50 μl 0.1% TritonX-100 (Beyotime, Shanghai, China), followed by 3% H₂O₂ (50 μl) blocking treatment. A terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) reaction solution (50 μl) was prepared according to the One Step TUNEL Apoptosis Assay Kit (Beyotime), to label samples with green fluorescence (Fluorescein isothiocyanate, FITC). DAPI (Biosharp, Hefei, China) was used for nuclear counter-staining. After mounting with anti-fade medium (Solarbio), sample images were observed and captured using a confocal microscope (Olympus, Tokyo, Japan) at 400× magnification.

CCK-8 assay

Cells were seeded (3×10⁴) in 96-well-plates, with five replicates for each group. After cell transfection and A/R treatment, the medium in each well was replaced with 100 μl complete DMEM plus 10 μl CCK-8 (Sigma-Aldrich, Darmstadt, Germany). Cells were incubated at 37°C in 5% CO₂ for 1 h, after which optical density (OD) at 450 nm was measured on an ELX-800 absorbance reader (BioTek, Winooski, VT, USA).

Cell apoptosis determination using flow cytometry

The Annexin V-FITC apoptosis detection kit (Beyotime) was used to detect cell apoptosis in H9c2 cells. Briefly, cells in 6-well-plates from each group were centrifuged, collected, and incubated with 200 μl Annexin V-FITC and 10 μl propidium iodide (PI) for 15 min at room temperature in the dark, followed by incubation on ice. Cells were gently resuspended 2–3 times to improve staining, and were processed by flow cytometry (NovoCyte Flow Cytometers, ACEA Biosciences, San Diego, CA, USA).
Total RNA was extracted using the high pure total RNA rapid extraction kit (BioTeke, Beijing, China), and reverse transcribed into cDNAs using M-MLV reverse transcriptase (Takara, Beijing, China) and RNase inhibitors (Takara). Oligo (dT)15 and RT primer were used for HMGB1 and miR-129-5p amplification during reverse transcription reactions. The RT primer was: 5′-GTTGCTCTGGTGAGGGTCCAGGTTACTCGACCACTCAGC, β-actin-F: GGAAGATTACTGCCCTGGCTCCTAGC, β-actin-R: GGCCGGACTCATCGTACTCCTGCTTG, HMGB1-R: TTTCATAGGGCTGCTTG, and starved 1 h before transfection. Lipofectamine™ 2000 transfection reagent (Invitrogen) was mixed with HMGB1 3′UTR (wt or mutant)-loaded luciferase reporter gene vector pmirGLO (Promega, Wisconsin, USA) and agomiR-129-5p (or agomiR NC) for co-transfection according to manufacturer instructions. The dual luciferase reporter assay kit (Promega) was used to assess relative luciferase activity in each group following manufacturer protocol.

**Statistical analysis**

In vivo histological and molecular examinations were performed with six replicates, and all experiments were carried out at least three times. All data were represented as the mean ± standard deviation (SD). Differences between three or more groups were analyzed using ordinary one-way ANOVA with post-hoc test of Tukey’s multiple comparison, and unpaired t-test was adopted to analyze differences between two groups. GraphPad Prism 8 software (San Diego, CA, USA) was used for image/figure processing. A value p < 0.05 was considered statistically significant.

### Results

miR-129-5p alleviates I/R injury in rat myocardium

Before establishing the rat I/R model, agomiR-129-5p and agomiR-NC were injected into rat myocardium. The relative expression of miR-129-5p was measured by real-time PCR, confirming that the transfection was effective (Fig. 2A). After 45 min ischemia and 3 h reperfusion, LV functional indices showed that I/R-induced significantly increased LVEDP, and reduced LVSP, EF, and FS could be recovered by agomiR-129-5p introduction (Fig. 2B). Serum enzyme activities of myocardial injury biomarker CK and LDH were also evaluated, showing that miR-129-5p upregulation led to a restoration of increased CK and LDH activities, after I/R (Fig. 2C). Besides, ELISA of serum levels of inflammatory cytokine TNF-α and IL-1β showed that exogenous miR-129-5p also attenuated the elevated serum TNF-α and IL-1β levels induced by I/R (Fig. 2D). We also quantified infarct size (TTC staining) of rat myocardium groups, and all experiments were carried out at least three times. All data were represented as the mean ± standard deviation (SD). Differences between three or more groups were analyzed using ordinary one-way ANOVA with post-hoc test of Tukey’s multiple comparison, and unpaired t-test was adopted to analyze differences between two groups. GraphPad Prism 8 software (San Diego, CA, USA) was used for image/figure processing. A value p < 0.05 was considered statistically significant.
miR-129-5p regulates myocardial I/R injury

Figure 2. miR-129-5p alleviates I/R injury in rat myocardium. A. Relative expression of miR-129-5p in rat myocardium samples were measured using real-time PCR before I/R modeling. B. Cardiac LV function was determined and represented as LVSP, LVEDP, EF, and FS. C. Enzyme activities of myocardial injury biomarker CK and LDH were checked through their detection kits. D. The inflammatory cytokines TNF-α and IL-1β in myocardium groups were measured by ELISA. E. TTC staining of myocardium tissues in each group. The percentage of infarct size was quantified and measured via IPP. F. The IF-TUNEL assay detected cell apoptosis in myocardium samples. Scale bar represented 50 μm. G. Real-time PCR quantification of miR-129-5p and HMGB1 relative expression in myocardium groups after I/R injury. H. HMGB1 relative protein levels in myocardium samples through Western blotting assay. * p < 0.05, ** p < 0.01, *** p < 0.001; ns, no statistical significance. All data were presented as the mean ± SD. One-way ANOVA was used to analyze data among all four groups.

LV, left ventricle; LVSP, left ventricular systolic pressure; LVEDP, left ventricular end-diastolic pressure; EF, ejection fraction; FS, fractional shortening; CK, creatinine kinase; LDH, lactate dehydrogenase; TNF-α, tumor necrosis factor-α; IL-1β, interleukin-1β; IPP, Image Pro-Plus; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; FITC, fluorescein isothiocyanate; I/R, ischemia-reperfusion.
sion, agomiR-129-5p administration revealed significantly different effects, increasing miR-129-5p itself and reducing HMGB1 expression. Western blotting also confirmed a similar miR-129-5p effect on HMGB1 expression at the protein level (Fig. 2H). Hence, these data suggested that miR-129-5p alleviated myocardium injury and restored infarct perturbations induced by I/R. These observations may also be related to decrease HMGB1 levels.

miR-129-5p affects H9c2 cell viability and apoptosis after A/R injury

Rat myocardial H9c2 cells were used as an in vitro cell A/R model. Before this, agomiR-129-5p transfection efficiency into H9c2 cells was evaluated by real-time PCR, showing that the transfection was efficient (Fig. 3A). Cell viability was checked after A/R treatment using CCK-8 assay and showed that miR-129-5p overexpression significantly restored cell viability after A/R injury (Fig. 3B). Annexin V/PI double staining, evaluating cell apoptosis under the same conditions, showed that agomiR-129-5p introduction alleviated cell apoptosis from approximately 23.3% to 7.8% after A/R (Fig. 3C). These results collectively indicated that miR-129-5p restored A/R-induced cell viability, and alleviated cell apoptosis in H9c2 cells in vitro, which is consistent with the I/R findings.

To investigate downstream molecule of miR-129-5p in H9c2 cells, the binding of miR-129-5p to HMGB1 was predicted online (TargetScan), and confirmed using dual luciferase reporter analysis (Fig. 4A). The results verified that HMGB1 was a direct target of miR-129-5p in H9c2 cells. Furthermore, relative protein and mRNA expression levels of HMGB1 were measured after H9c2 cells were transfected with agomiR-129-5p and antagomiR-129-5p, showing that miR-129-5p overexpression led to reduced HMGB1, whilst miR-129-5p knockdown significantly increased its levels at both translational (Fig. 4B) and transcriptional levels (Fig. 4C). These results suggested that miR-129-5p directly targeted HMGB1 and had a reverse correlation with the HMGB1 expression.

**HMGB1 overexpression reverses the effects of miR-129-5p in H9c2 cells after A/R injury**

To evaluate how HMGB1 affected miR-129-5p regulation in A/R-treated H9c2 cells, cells were co-transfected with agomiR-129-5p and the HMGB1 overexpression plasmid. High co-transfection efficiency was observed, as shown by significantly upregulated miR-129-5p and HMGB1, respectively (Fig. 5A). Cell viability and apoptosis were measured after A/R

![Figure 3. miR-129-5p affects H9c2 cell viability and apoptosis after A/R injury. A. Expression levels of miR-129-5p were assessed after H9c2 cell transfection with agomiR-129-5p. B. Cell viability was measured through CCK-8 assay after A/R treatment of transfected H9c2 cells. C. Cell apoptosis was detected by Annexin V-FITC/PI double staining and measured using flow cytometry after A/R treatment in each cell group. *p < 0.05, **p < 0.01, ***p < 0.001. Data were presented as the mean ± SD. One-way ANOVA was used for data analysis. A/R, anoxia-reoxygenation.](image-url)
miR-129-5p regulates myocardial I/R injury

treatment. These data suggested that HMGB1 overexpression decreased the cell viability (Fig. 5B), but enhanced cell apoptosis (Fig. 5C), whilst miR-129-5p was simultaneously overexpressed. Combined with the findings from Figure 3, these data suggested that HMGB1 overexpression reversed the effects of miR-129-5p on rat A/R-injured cardiomyocytes.

**Discussion**

Our work investigated the role of miR-129-5p in rat myocardial I/R injury, and whether HMGB1 participated in this miR-129-5p-mediated regulation. To resolve these questions, we established an in vivo rat myocardial I/R model and an

---

**Figure 4.** miR-129-5p targets and negatively regulates HMGB1 in H9c2 cells. **A.** A dual luciferase reporter assay was performed to evaluate miR-129-5p binding to HMGB1 in H9c2 cells. **B.** H9c2 cells were transfected with agomiR-129-5p and antagomiR-129-5p. Western blotting assay evaluated relative protein expression of HMGB1 in different groups. **C.** Real-time PCR quantified the relative mRNA expression of HMGB1 in each group. *p < 0.05, **p < 0.01, ***p < 0.001; ns, no statistical significance. Data were presented as the mean ± SD. One-way ANOVA was used for data analysis. WT, wild-type; MUT, mutant.

**Figure 5.** Overexpression of HMGB1 reverses the effects of miR-129-5p in H9c2 cells after A/R injury. **A.** Rat H9c2 cells were co-transfected with agomiR-129-5p and the HMGB1 overexpression plasmid. Relative expression of miR-129-5p and HMGB1 was assessed before proceeding. **B.** A CCK-8 assay evaluated cell viability after co-transfection, and A/R treatment. **C.** Annexin V-FITC/PI double staining assessed cell apoptosis under the same conditions. *p < 0.05, **p < 0.01, ***p < 0.001; ns, no statistical significance. Data were presented as the mean ± SD. One-way ANOVA and unpaired t-test methods were used for data analysis. A/R, anoxia-reoxygenation.
in vitro cardiomyocyte A/R model. These models suggested that miR-129-5p alleviated rat myocardial I/R injury by directly binding to HMGB1, and negatively regulated its expression. Initially, rats with I/R injury of the myocardium showed that miR-129-5p overexpression restored cardiac injury indices and enzyme activities, attenuated inflammatory effects and infarct size caused by I/R, and also reduced cell apoptosis in rat myocardium tissues. Moreover, overexpressed miR-129-5p recovered cell viability and apoptosis in H9c2 cells after A/R treatment. Although miR-129 has been well-characterized as a tumor suppressor in many cancers (Kohkkan et al. 2016; Liu et al. 2018; Li et al. 2019), its role in hypoxia or ischemia-related diseases has seen an increase in research activity. During ischemic cerebral injury, miR-129 affects neural cell apoptosis through regulating the apoptotic factors, Bcl-2 and caspase-3 (Zhai et al. 2012). Similarly, miR-129 also relieves neuro-inflammatory spinal cord damage in a mouse model of spinal cord I/R injury (Li et al. 2017). In H9c2 cells with H2O2 treatment, miR-129 reduced cell injury and involved in PI3K/AKT/mTOR signaling pathway, providing a new approach to ischemia heart disease treatment (Zhang et al. 2018). These studies suggested a strong power of miR-129 to modulate several vital signaling circuits related to cellular development in I/R-related diseases. Accordingly, as outlined in this study, its function during I/R injury at the myocardium, suggests that miR-129 may also modify I/R injury at this location, confirming our hypothesis that overexpressed miR-129-5p alleviates myocardial I/R injury to enhance cell viability and suppress cell apoptosis in rats.

The binding effects of miR-129-5p towards HMGB1 were verified in H9c2 cells, and miR-129-5p was shown to be reversely correlated with the expression of HMGB1. Although agomiR-129-5p introduction in H9c2 cells recovered cell viability and apoptosis after A/R, further HMGB1 overexpression reversed these effects, indicating that HMGB1 has an important role in the miR-129-5p mediated regulation of rat myocardial I/R injury. Actually, the link between miR-129-5p and HMGB1 has already been reported in several cancers and diseases, e.g. colon cancer, gastric cancer, autoimmune encephalomyelitis-related epilepsy, and neuropathic pain, etc. (Liu et al. 2017b; Wu et al. 2018; Wang et al. 2019; Tian et al. 2020). It is noteworthy that miR-129-5p also improves heart function and alleviates oxidative stress and inflammation in rats with chronic heart failure through regulating HMGB1 (Xiao et al. 2019). However, this regulatory mechanism has not been investigated in cardiac I/R injury, until now, where we observed the cardioprotective role of miR-129-5p in heart injury.

As a well-known damage-associated molecular pattern (DAMP) molecule, HMGB1 secreted by necrosis cells, macrophages, or damaged cells mediates strong inflammatory responses through binding to the receptor for advanced glycation end-products (RAGE) or toll-like receptors (such as TLR2, TLR4, and TLR5) (Lee et al. 2015; Das et al. 2016). Previous studies demonstrated that HMGB1-mediated signaling pathways are related to cellular regulation after I/R injury in several organs, including the liver, spinal cord and heart (Andrassy et al. 2008; Chen et al. 2011; Zhao et al. 2017; Xie et al. 2018). Andrassy et al. (2008) indicated that HMGB1 levels were increased in the heart after hypoxia or ischemia treatment both in vivo and in vitro, which agreed with our HMGB1 expression data in myocardial I/R injury. Hence, when miR-129-5p directly binds to HMGB1 in cardiomyocytes, it may also inhibit HMGB1-mediated downstream pathways via RAGE or TLRs, to decrease following inflammatory responses, thereby attenuating cellular damages. Although the downstream mechanism of miR-129-5p/HMGB1 axis remains to be verified in myocardial I/R injury model, its existence is highly likely, based on literature data and our evidence. Indeed, as miRNAs usually target several genes and there are dozens of predicted targets of miR-129-5p, there may be some other genes acting downstream of miR-129-5p to regulate cardiac I/R injury together, which, however, requires further exploration.

As previously described, myocardial reperfusion therapy has a high risk to cause reperfusion injury in AMI patients, which may induce secondary heart failure or even death. Since non-coding RNAs have been widely implicated in various cellular activities and disease etiologies, non-coding RNA-based gene therapy is considered as a new approach to treat them. In the heart, several miRNAs are dysregulated during cardiac I/R injury, which may be treated as key regulators or biomarkers in these cardiac diseases (Colpaert and Calore 2019; Kura et al. 2020). For example, dysregulation of miR-1, miR-21, and miR-133 was observed in MI heart tissue. Although the precise role of miR-1 is still uncertain in cardiac I/R injury, it is undeniable that miR-1 is closely related to the myocardial I/R processes, and may regulate the adaptive mechanisms after heart injury (Kura et al. 2020). Other important regulators of cardiac I/R injury include miR-21 and miR-133, which are believed to exert cardioprotective functions in MI, mainly through inhibition of apoptosis (Colpaert and Calore 2019; Kura et al. 2020). Combined with our study, down-regulated miR-129 was detected in vivo after I/R injury, when compared with the Sham group. Overexpressed miR-129 ameliorated cardiac injury and also protected cells from apoptosis both in vivo and in vitro, by targeting HMGB1. These observations may underpin a new targeted mechanism for myocardium reperfusion injury-related gene therapy.

In conclusion, we investigated the role of miR-129-5p during rat myocardial I/R injury, both in vivo and in vitro. It was shown that injected agomiR-129-5p alleviated cardiac damage, inflammatory responses, and myocardial infarct size after I/R injury, miR-129-5p directly targeted HMGB1 and negatively regulate its expression in H9c2 cells. miR-129-5p
overexpression in A/R treated cardiomyocytes relieved cell apoptosis and restored cell viability, which appeared to be aggravated by further HMGB1 overexpression. Therefore, these results suggest that in rats, miR-129-5p ameliorates cardiac damage induced by I/R, and protects cardiomyocytes from cell apoptosis by targeting HMGB1. These data provide potential targets for new myocardium reperfusion injury-related therapies.

Acknowledgements. This research was supported by a grant from the Health Commission of Hebei Province (Grant No. 20200309).

Conflict of interests. None.

References


https://doi.org/10.1016/j.prp.2018.12.024

https://doi.org/10.1002/jcp.26383

https://doi.org/10.1007/s00335-019-09817-0

https://doi.org/10.1002/ptr.6161

https://doi.org/10.1056/NEJMra071667

https://doi.org/10.1007/s12031-019-01403-y

https://doi.org/10.1016/j.bbrc.2018.10.085

https://doi.org/10.1038/srep46272

https://doi.org/10.1002/jcb.28075

https://doi.org/10.1002/jcb.26704

Received: March 2, 2020
Final version accepted: June 14, 2020